Linio Biotech develops Tience, a sterile cell-free tissue product that promotes the biological regeneration of damaged skin, addressing issues such as severe scars and skin defects. This technology enhances healing and improves skin texture, offering a safe alternative to traditional autologous methods like PRP and fat grafting.
Funding
$9.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of people suffer from skin damage due to surgeries, trauma, aging, and environmental factors, leading to scars, skin defects, and compromised skin function. Current autologous methods like PRP and fat grafting have limitations in terms of safety and efficacy.
Solution
Linio Biotech offers Tience, a sterile, cell-free tissue product designed to promote biological regeneration of damaged skin. This regenerative aesthetic solution enhances the skin's natural healing processes, leading to improved skin texture and quality. Tience provides a scientifically proven and safe alternative to traditional autologous methods, addressing severe scars, skin defects, and aged skin. By supporting the skin's ability to restore itself, Tience aims to improve the quality of life for individuals with compromised skin.
Target Audience
The primary target audience includes individuals suffering from severe scars, skin defects, and aged skin, as well as medical professionals in the field of regenerative aesthetics.
Features
- Sterile, cell-free formulation for enhanced safety
- Promotes biological regeneration of damaged skin tissue
- Improves skin texture and overall skin quality
- Alternative to autologous methods like PRP and fat grafting
- Designed for treatment of severe scars, skin defects, and aged skin